Browsing by Author "Bellosillo Paricio, Beatriz"

Sort by: Order: Results:

  • Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
    Van Emburgh, Beth O.; Vidal Barrull, Joana; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Montagut Viladot, Clara; Bardelli, Alberto (Nature Publishing Group, 2016)
    Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of ...
  • Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
    Fernández Rodríguez, M. Concepción; Salar Silvestre, Antonio; Navarro, Alfons; Gimeno Vázquez, Eva; Pairet García, Silvia; Camacho Díaz, Laura; Ferraro Rosset, Mariana Paola; Serrano Figueras, Sergi; Besses Raebel, Carles; Bellosillo Paricio, Beatriz; Sanchez Gonzalez, Blanca (Taylor & Francis, 2016)
    Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. ...
  • BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent
    Margalef González, Pol, 1985-; Colomer Montañà, Carlota, 1990-; Villanueva, Alberto; Montagut Viladot, Clara; Iglesias Coma, Mar; Bellosillo Paricio, Beatriz; Salazar, Ramón; Martínez Iniesta, María; Bigas Salvans, Anna; Espinosa Blay, Lluís (American Association for the Advancement of Science, 2015)
    KRAS mutations contribute to cell proliferation and survival in numerous cancers, including colorectal cancers (CRC). One pathway through which mutant KRAS acts is an inflammatory pathway that involves the kinase IKK and ...
  • Cell-free DNA for genomic analysis in primary mediastinal large B-cell lymphoma
    Rivas-Delgado, Alfredo; Nadeu, Ferran; Andrade-Campos, Marcio; López, Cristina; Enjuanes¸ Anna; Mozas, Pablo; Frigola, Gerard; Colomo Saperas, Luis Alberto; Sánchez González, Blanca; Villamor, Neus; Beà, Sílvia; Campo, Elias; Salar Silvestre, Antonio; Giné, Eva; López Guillermo, Armando; Bellosillo Paricio, Beatriz (MDPI, 2022)
    High-throughput sequencing of cell-free DNA (cfDNA) has emerged as a promising noninvasive approach in lymphomas, being particularly useful when a biopsy specimen is not available for molecular analysis, as it frequently ...
  • Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
    Angona Figueras, Anna; Álvarez Larrán, Alberto; Bellosillo Paricio, Beatriz; Longarón Rozalen, Raquel; Camacho Díaz, Laura; Fernández Rodríguez, M. Concepción; Pairet García, Silvia; Besses Raebel, Carles (Elsevier, 2016)
    Mutations in JAK2 or CALR are observed in patients with myeloproliferative neoplasms (MPN). To get further insight in the dynamics of the mutant clone, we assessed the mutant allele burden in hematopoietic stem cells (HSCs), ...
  • Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance.
    Gallardo Hernández, Fernando; Padrón, Andreina; Garcia Carbonell, Ricard; Rius, Cristina; González-Pérez, Abel; Arumí, Montserrat; Iglesias Coma, Mar; Nonell Mazelón, Lara; Bellosillo Paricio, Beatriz; Segura Tigell, Sonia; Pujol Vallverdú, Ramon Maria; López Bigas, Núria; Bertran, Joan; Bigas Salvans, Anna; Espinosa Blay, Lluís (Impact Journal, 2015)
    Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found ...
  • Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall Aguilar, David; Vidal Barrull, Joana; Gallardo Hernández, Fernando; Zuccarino, Flavio; Arumí, Montserrat; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Montagut Viladot, Clara (BioMed Central, 2016)
    BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 ...
  • Diagnostic usefulness of immunohistochemical evaluation of CD1a antigen and polyclonal anti-leishmania antibodies in cutaneous leishmaniasis
    López Trujillo, Emilio; Gonzàlez Farré, Mònica; Pujol, Ramón M.; Bellosillo Paricio, Beatriz; Fisa, Roser; Riera Carro, Cristina; Alcover, Magdalena; Barranco Sanz, Luis Carlos; Martin-Ezquerra, Gemma (Histology and Histopathology, 2021)
    Background: Different immunohistochemical markers to detect amastigotes in cutaneous leishmaniasis have been proposed with variable diagnostic usefulness. Objectives: To evaluate the diagnostic usefulness of immunohistochemical ...
  • Diagnostic value of genotypic analysis in primary cutaneous lymphomas using standardized BIOMED-2 polymerase chain reaction protocols: experience in daily clinical practice
    López-Aventín, Daniel; Gallardo Hernández, Fernando; Colomo Saperas, Luis Alberto; Moragón, Ester; Vela Ortíz, María del Carmen; Duran Jordà, Xavier, 1974-; Bellosillo Paricio, Beatriz; Pujol Vallverdú, Ramon Maria (Society for Publication of Acta Dermato-Venereologica, 2021)
    BIOMED-2 Concerted Action BMH4-CT98-3936 (BIOMED-2) PCR protocols are an important diagnostic tool in the evaluation of cutaneous lymphomas. The aim of this study was to assess the diagnostic value of the genotyping results ...
  • Effect of mutation order on myeloproliferative neoplasms.
    Ortmann, Christina A.; Green, Anthony R.; Bellosillo Paricio, Beatriz; Besses Raebel, Carles (Massachusets medical society, 2015)
    BACKGROUND: Cancers result from the accumulation of somatic mutations, and their properties are thought to reflect the sum of these mutations. However, little is known about the effect of the order in which mutations are ...
  • EGFR and KRAS mutations in lung parenchyma of subjects with EGFR/KRAS wild-type lung adenocarcinoma
    Chalela Rengifo, Roberto José, 1985-; González-García, José Gregorio; Khilzi, Karys; Curull Serrano, Víctor; Sánchez Font, Albert; Longarón Rozalen, Raquel; Rodrigo Calvo, Maria Teresa; Martín-Ontiyuelo, Clara; Gea Guiral, Joaquim; Bellosillo Paricio, Beatriz (Frontiers, 2021)
    The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present ...
  • EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma
    Chalela Rengifo, Roberto José, 1985-; Bellosillo Paricio, Beatriz; Curull Serrano, Víctor; Longarón Rozalen, Raquel; Pascual Guàrdia, Sergi, 1979-; Badenes Bonet, Diana, 1987-; Arriola Aperribay, Edurne; Sánchez-Font, Albert; Pijuan Andujar, Lara; Gea Guiral, Joaquim (MDPI, 2019)
    Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout ...
  • Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene epigenetically regulated
    Martínez-Calle, Nicolás; Pascual, Marien; Ordóñez, Raquel; San José-Enériz, Edurne; Kulis, Marta; Miranda, Estíbaliz; Guruceaga, Elisabeth; Segura, Víctor; Larráyoz, María José; Bellosillo Paricio, Beatriz; Calasanz, María José; Besses Raebel, Carles; Rifón, José; Martín-Subero, José I.; Agirre, Xabier; Prosper, Felipe (Ferrata Storti Foundation, 2019)
    In this study we have interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpGs corresponding to 10,253 genes between myelofibrosis ...
  • Evaluating the potential of polygenic risk score to improve colorectal cancer screening
    Arnau-Collell, Coral; Bellosillo Paricio, Beatriz; Hernández Rodríguez, Cristina; Castellví Bel, Sergi (American Association for Cancer Research (AACR), 2022)
    Background: colorectal cancer has high incidence and associated mortality worldwide. Screening programs are recommended for men and women over 50. Intermediate screens such as fecal immunochemical testing (FIT) select ...
  • Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
    Rodríguez-Sevilla, Juan José; Fernández Rodríguez, M. Concepción; Bento, Leyre; Díez-Feijóo, Ramón; Felipe Pinzon, Sergio; Gibert Fernandez, Joan 1988-; Fernández-Ibarrondo, Lierni; Lafuente, Marta; Ferrer Del Alamo, Ana; Sánchez González, Blanca; Gimeno Vázquez, Eva; Sainz, Juan; Ramos-Asensio, Rafael; García, Juan Fernando; Colomo Saperas, Luis Alberto; Bellosillo Paricio, Beatriz; Gutierrez, Antonio; Salar Silvestre, Antonio (American Society of Hematology, 2022)
    Several clinical risk models have been proposed to predict outcome in follicular lymphoma (FL). The development of Next Generation Sequencing (NGS) technologies has allowed the integration of somatic gene mutations in ...
  • Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients
    Montero, Maria Milagro; Hardy-Werbin, Max; Gonzalez-Gallardo, Soledad; Torres, Erica; Rueda, Rebeca; Arenas-Miras, María Del Mar; Arietta-Aldea, Itziar; Castañeda, Silvia; Gómez Junyent, Joan; Gómez-Zorrilla, Silvia; Guerri-Fernandez, Robert; Sánchez-Martínez, Francesca; López Montesinos, Inmaculada; Pelegrín, Iván; Sendra, Elena; Sorlí, Luisa; Villar García, Judit; Bellosillo Paricio, Beatriz; Horcajada Gallego, Juan Pablo (Nature Research, 2023)
    Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay ...
  • Gal-1 expression analysis in the GLIOCAT multicenter study: Role as a prognostic factor and an immune-suppressive biomarker
    Martínez Bosch, Neus; Alameda Quitllet, Francisco; Arumí Uría, Montserrat; Bellosillo Paricio, Beatriz; Menéndez, Silvia; Esteve-Codina, Anna; Martínez-García, Maria; Navarro Medrano, Pilar (MDPI, 2023)
    Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a ...
  • Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
    Brammeld, Jonathan S.; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Vidal Barrull, Joana; Montagut Viladot, Clara; McDermott, Ultan (Cold Spring Harbor Laboratory Press (CSHL Press), 2017)
    Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations that have the potential to ...
  • Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea
    Alvarez-Larrán, Alberto; Díaz-González, Alvaro; Such, Esperanza; Mora, Elvira; Andrade-Campos, Marcio; García-Hernández, Carmen; Gómez-Casares, Maria-Teresa; García-Gutiérrez, Valentín; Carreño-Tarragona, Gonzalo; Garrote, Marta; Fernández-Ibarrondo, Lierni; Cervera, José; Bellosillo Paricio, Beatriz; Cervantes, Francisco; Hernández-Boluda, Juan Carlos; MPN Spanish Group (GEMFIN) (Nature Research, 2020)
  • HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
    Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...